A proteomic approach to identifying new drug targets (potentiating topoisomerase II poisons)

Author: JENKINS, J R

Source: British Journal of Radiology, Volume 81, Supplement 1, October 2008 , pp. S69-S77(9)

Publisher: British Institute of Radiology

Buy & download fulltext article:

This article is hosted on another website.

You may be required to register, activate a subscription or purchase the article before you can obtain the full text.

Proceed

Abstract:

Topoisomerase II poisons are an established part of best clinical practice for the treatment of a number of solid tumours and haematological malignancies. However, toxicity and resistance to chemotherapeutic drugs often complicate the treatment. Furthermore, topoisomerase II poisons can also induce sister chromatid exchange, chromosomal recombination and chromosome aberrations and are associated with a significant risk of secondary leukaemia. It would therefore be of great clinical benefit if the efficacy of topoisomerase II inhibitors could be enhanced without the increased toxic side effects. It is proposed that clinical agents targeting topoisomerase II can be enhanced by inhibiting proteins that modulate topoisomerase II. The aim is to identify proteins, that by the nature of their interaction with topoisomerase II, represent putative drug targets.

Document Type: Research article

DOI: http://dx.doi.org/10.1259/bjr/76952340

Publication date: 2008-10-01